145 related articles for article (PubMed ID: 15865427)
1. Role of the intramolecular hydrogen bond network in the inhibitory power of chymotrypsin inhibitor 2.
Radisky ES; Lu CJ; Kwan G; Koshland DE
Biochemistry; 2005 May; 44(18):6823-30. PubMed ID: 15865427
[TBL] [Abstract][Full Text] [Related]
2. Binding, proteolytic, and crystallographic analyses of mutations at the protease-inhibitor interface of the subtilisin BPN'/chymotrypsin inhibitor 2 complex.
Radisky ES; Kwan G; Karen Lu CJ; Koshland DE
Biochemistry; 2004 Nov; 43(43):13648-56. PubMed ID: 15504027
[TBL] [Abstract][Full Text] [Related]
3. The role of the protein core in the inhibitory power of the classic serine protease inhibitor, chymotrypsin inhibitor 2.
Radisky ES; King DS; Kwan G; Koshland DE
Biochemistry; 2003 Jun; 42(21):6484-92. PubMed ID: 12767231
[TBL] [Abstract][Full Text] [Related]
4. Structural and biochemical studies of inhibitor binding to human cytomegalovirus protease.
Khayat R; Batra R; Qian C; Halmos T; Bailey M; Tong L
Biochemistry; 2003 Feb; 42(4):885-91. PubMed ID: 12549906
[TBL] [Abstract][Full Text] [Related]
5. Recombinant chymotrypsin inhibitor 2: expression, kinetic analysis of inhibition with alpha-chymotrypsin and wild-type and mutant subtilisin BPN', and protein engineering to investigate inhibitory specificity and mechanism.
Longstaff C; Campbell AF; Fersht AR
Biochemistry; 1990 Aug; 29(31):7339-47. PubMed ID: 2207109
[TBL] [Abstract][Full Text] [Related]
6. Contribution of peptide bonds to inhibitor-protease binding: crystal structures of the turkey ovomucoid third domain backbone variants OMTKY3-Pro18I and OMTKY3-psi[COO]-Leu18I in complex with Streptomyces griseus proteinase B (SGPB) and the structure of the free inhibitor, OMTKY-3-psi[CH2NH2+]-Asp19I.
Bateman KS; Huang K; Anderson S; Lu W; Qasim MA; Laskowski M; James MN
J Mol Biol; 2001 Jan; 305(4):839-49. PubMed ID: 11162096
[TBL] [Abstract][Full Text] [Related]
7. Engineering of the pH optimum of Bacillus cereus beta-amylase: conversion of the pH optimum from a bacterial type to a higher-plant type.
Hirata A; Adachi M; Utsumi S; Mikami B
Biochemistry; 2004 Oct; 43(39):12523-31. PubMed ID: 15449941
[TBL] [Abstract][Full Text] [Related]
8. Changing the inhibitory specificity and function of the proteinase inhibitor eglin c by site-directed mutagenesis: functional and structural investigation.
Heinz DW; Hyberts SG; Peng JW; Priestle JP; Wagner G; Grütter MG
Biochemistry; 1992 Sep; 31(37):8755-66. PubMed ID: 1390662
[TBL] [Abstract][Full Text] [Related]
9. Contribution of residues in the reactive site loop of chymotrypsin inhibitor 2 to protein stability and activity.
Jackson SE; Fersht AR
Biochemistry; 1994 Nov; 33(46):13880-7. PubMed ID: 7947796
[TBL] [Abstract][Full Text] [Related]
10. Stabilized variant of Streptomyces subtilisin inhibitor and its use in stabilizing subtilisin BPN'.
Ganz PJ; Bauer MD; Sun Y; Fieno AM; Grant RA; Correa PE; Laskowski M; Saunders CW
Protein Eng Des Sel; 2004 Apr; 17(4):333-9. PubMed ID: 15187224
[TBL] [Abstract][Full Text] [Related]
11. Differences in binding modes of enantiomers of 1-acetamido boronic acid based protease inhibitors: crystal structures of gamma-chymotrypsin and subtilisin Carlsberg complexes.
Stoll VS; Eger BT; Hynes RC; Martichonok V; Jones JB; Pai EF
Biochemistry; 1998 Jan; 37(2):451-62. PubMed ID: 9425066
[TBL] [Abstract][Full Text] [Related]
12. Solution studies of chymotrypsin inhibitor-2 glutamine insertion mutants show no interglutamine interactions.
Gordon-Smith DJ; Carbajo RJ; Stott K; Neuhaus D
Biochem Biophys Res Commun; 2001 Jan; 280(3):855-60. PubMed ID: 11162601
[TBL] [Abstract][Full Text] [Related]
13. The structural basis of a conserved P2 threonine in canonical serine proteinase inhibitors.
Brauer AB; Nievo M; McBride JD; Leatherbarrow RJ
J Biomol Struct Dyn; 2003 Apr; 20(5):645-56. PubMed ID: 12643767
[TBL] [Abstract][Full Text] [Related]
14. The 0.78 A structure of a serine protease: Bacillus lentus subtilisin.
Kuhn P; Knapp M; Soltis SM; Ganshaw G; Thoene M; Bott R
Biochemistry; 1998 Sep; 37(39):13446-52. PubMed ID: 9753430
[TBL] [Abstract][Full Text] [Related]
15. Kinetics of factor Xa inhibition by recombinant tick anticoagulant peptide: both active site and exosite interactions are required for a slow- and tight-binding inhibition mechanism.
Rezaie AR
Biochemistry; 2004 Mar; 43(12):3368-75. PubMed ID: 15035608
[TBL] [Abstract][Full Text] [Related]
16. Intramolecular orbital alignments in serine protease/protein inhibitor complexes.
Fan YH; Grégoire CA; Haseltine J
Bioorg Med Chem; 2004 Jun; 12(11):3097-106. PubMed ID: 15142568
[TBL] [Abstract][Full Text] [Related]
17. Structural and dynamic changes in human annexin VI induced by a phosphorylation-mimicking mutation, T356D.
Freye-Minks C; Kretsinger RH; Creutz CE
Biochemistry; 2003 Jan; 42(3):620-30. PubMed ID: 12534274
[TBL] [Abstract][Full Text] [Related]
18. Spacer Asn determines the fate of Kunitz (STI) inhibitors, as revealed by structural and biochemical studies on WCI mutants.
Dasgupta J; Khamrui S; Dattagupta JK; Sen U
Biochemistry; 2006 Jun; 45(22):6783-92. PubMed ID: 16734415
[TBL] [Abstract][Full Text] [Related]
19. Variable contributions of tyrosine residues to the structural and spectroscopic properties of the factor for inversion stimulation.
Boswell S; Mathew J; Beach M; Osuna R; Colón W
Biochemistry; 2004 Mar; 43(10):2964-77. PubMed ID: 15005633
[TBL] [Abstract][Full Text] [Related]
20. Active site binding loop stabilization in the subtilisin inhibitor eglin c: structural and functional studies on specifically designed mutants in complex with subtilisin and the uncomplexed inhibitor.
Hipler K; Priestle JP; Rahuel J; Grütter MG
Adv Exp Med Biol; 1996; 379():43-7. PubMed ID: 8796309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
